• H2020
• Excellent Science
• European Research Council

Breathtec Biomedical Inc. has stated its aims to improve and further develop breath test medical devices for detecting various diseases.

Diagnosis by breath test is both a growing market and area of medical research that is improving identification in conditions such as lung and breast cancers, tuberculosis, diabetes, liver disease and neuro-degenerative diseases such as Alzheimer’s and Parkinson’s. Guy LaTorre, CEO of Breathtec, has highlighted his hopes for this relatively new area of science.

He said: “The company is nurturing an expanding pipeline of innovative technology during a period of intense interest in the emerging field of breath analysis. The focus … is on early stage, accessible and non-invasive diagnostics across a wide range of diseases. Successful commercialisation of this technology is poised to offer a truly profound impact on personal health care delivery.”

Breath tests can detect specific biomarkers in disease diagnosis, as could the more traditional blood test. Unlike blood tests, however, breath tests are non-invasive, non-intrusive and significantly more time and cost efficient for doctors and patients.

Professor Hossam Haick of the Laboratory of Nanomaterial-Based Devices has contributed to non-invasive screening through his development of artificially intelligent nano-array technology. He has been the recipient of the prestigious Marie Curie Excellence Award, the European Research Council (ERC) Award, and the FP-7 and Horizon 2020 consortium Awards.

Haick’s research interests include nano-array devices for screening, diagnosis and monitoring of disease, nanomaterial-based chemical (flexible) sensors, electronic skin, breath analysis, volatile biomarkers and molecule-based electronic devices.

Breathtec announced clinical trials for its new product NA-NOSE, which is an advanced stage, nanotechnology-based breath analysis device from the Technion – Israel Institute of Technology. The Ntrials will involve an intensive research review into NA-NOSE, which has been in-licensed by the company.